Today's Weak On High Volume Stock: Synageva BioPharma (GEVA)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Synageva BioPharma ( GEVA) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Synageva BioPharma as such a stock due to the following factors:

  • GEVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $30.2 million.
  • GEVA has traded 56,431 shares today.
  • GEVA is trading at 5.62 times the normal volume for the stock at this time of day.
  • GEVA is trading at a new low 3.03% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GEVA with the Ticky from Trade-Ideas. See the FREE profile for GEVA NOW at Trade-Ideas

More details on GEVA:

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases.

The average volume for Synageva BioPharma has been 261,700 shares per day over the past 30 days. Synageva BioPharma has a market cap of $3.0 billion and is part of the health care sector and drugs industry.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null

More from Markets

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

Your Need to Know - Forward Look

Your Need to Know - Forward Look

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low

State Street Shares Fall as Earnings Fail to Meet Expectations

State Street Shares Fall as Earnings Fail to Meet Expectations